Etoposide-platinum + durvalumab (extensive SCLC, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CARBOPLATIN DRUG-ETOPOSIDE DRUG-DURVALUMAB |
|---|
| ID | REG-EP-DURVA-SCLC |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-SCLC-2021 SRC-NCCN-SCLC-2025 |
Notes
CASPIAN: median OS 13.0 (durva) vs 10.3 months (EP). ESMO preferred ICI; NCCN considers atezo and durva equivalent.
Used By
Indication
IND-SCLC-EXTENSIVE-1L- IND-SCLC-EXTENSIVE-1L
Regimen
REG-CE-SCLC- Carboplatin + etoposide (SCLC, 1L)